Invesco Biotechnology & Genome ETF PBE
Set alert
At close · Nov 2
After hours · Nov 2, 7:30 PM ET
- YTD
- +23.10%
- 1 year
- +35.14%
- Open
- 102.67
- Prev close
- 102.50
- Mkt cap
- 307.51M
- Vol
- 28.70K
- Avg vol
- 20.01K
- EPS
- 3.66
- P/E
- 27.61
- Div yield
- 0.00%
More statistics
- Low
- 101.10
- High
- 102.86
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 69.17
- 200-d avg
- 67.04
Discussion (1)
Sign in to join the discussion
VICKY HANUKA PBE 3 years ago #1$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.